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1. Introduction 
The first use of hypothermia in cardiac surgery is attributed to Dr. John Lewis who 
performed an atrial septal defect closure on September 2, 1952 at the University of 
Minnesota (Gott, 2005). 
Cardiopulmonary by-pass (CPB) and hypothermic cardio-circulatory arrest (HCCA) has 
been introduced for the first time in clinical practice for aortic arc substitution (Pierangeli et 
al., 1974). More recently the same technique has been proposed to remove atrial thrombi 
originated from renal carcinomas (Marshall et al., 1984), adrenal carcinomas (Shahinian et 
al., 1989), hepatocellular carcinoma (Hamazaki et al., 1995) and other abdominal 
malignancies such as caval leiomyosarcoma, uterine endometrial sarcoma or intravenous 
leiomyomatosis, ovarian or testicular tumors (Hassan et al.,, 2010; Vargas-Barron et al., 1990; 
Ariza et al., 1982; Kanda et al., 1991).   
There is still a debate pro and cons the use of hypothermic arrest with some favours the 
normothermic (Lubahn et al., 2006; Stewart et al., 1991) and some others the hypothermic, 
because of the operative field appears better exposed and almost completely bloodless so 
the blood loss resulted much lower. Furthermore they claim a better visualization of some 
critical areas with an easier removal of the tumoural thrombus, that may invade the hepatic 
veins or the coronaric sinus, may either remain attached to the tricuspid valve or may have 
embolized into the pulmonary artery (Chiappini et al., 2002; Kalkat et al., 2008; Leo et al., 
2010; Topcouglu et al., 2004). In all these occasions HCCA offers the possibility of a better 
tumoural cleaning with the possibility of R0 resection. The incomplete removal of this 
tumoural thrombi in fact is correlated to an early recurrence and a worst postoperative 
survival (Skinner et al., 1989). Furthermore the hepatic, renal and splacnic damage from 
warm ischemia due to the Pringle’s manoeuvre and/or aortic/mesenteric cross-clamping 
(usually necessary when CPB is used without cardio-circulatory arrest) is reduced when the 
HCCA is instead used (Chiappini et al., 2002, Davlouros et al., 2005). This permits its use 
even in the setting of mild hepatic damage (Leo et al., 2010). 
2. Kidney  
Tumour thrombus extension in the inferior vena cava (IVC) occurs in 4 % to 10% of patients 
with renal cell carcinoma (RCC) (Marshall et al., 1988). The cephalic extension of tumour 
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thrombus in RCC was first defined in 1987 by Neves and Zincke (Neves & Zincke, 1987) and 
classified in four levels (level I : thrombus at the level of the renal vein, level II : thrombus 
extending into the infra-hepatic IVC, level III : thrombus extending into the retro-hepatic 
IVC, level IV : intra-atrial thrombus (suprahepatic IVC involvement or right atrium 
thrombus). Libertino classification system (Moinzadeh & Libertino, 2004) distinguishes: 
renal vein only involvement, level I caval involvement (IVC below the diaphragm), level II 
caval involvement (IVC above the diaphragm) and level III involvement (when the 
thrombus reaches the atrium).  
Recently an updated staging system by the American Joint Committee on Cancer (AJCC) 
and the “Union International Contre le Cancer” (UICC) was utilized and the current staging, 
according to the 2009 UICC/AJCC TNM staging classification system, designates renal vein 
involvement as pT3a Level III, when the thrombus involves the intra-hepatic portion of the 
IVC but below the diaphragm is designated as p T3b, while level IV when the thrombus 
extends above the diaphragm, as T3c.  The thrombus may extend as far as the right atrium 
(IV level) in 1% of patients with RCC. Accurate information about the presence and 
complete extent of IVC involvement is essential for surgical planning. Routine CT scanning 
and abdominal ultrasonography are less reliable in delineating the cephalic extent of the 
thrombus. Contrast inferior venacavography is an accurate, but invasive, diagnostic tool and 
a single anterograde study may be insufficient in complete caval obstruction. Occasionally 
has been employed trans oesophageal echocardiography and trans-abdominal colour flow 
Doppler ultrasonography. MRI has become the preferred, non invasive, diagnostic study 
though its frequent inability to differentiate actual invasion of the vena cava wall which is 
generally associate with a poor prognosis. Contrast inferior venography is reserved for 
patients in whom MRI finings are equivocal or for whom MRI is contraindicated. Another 
option in this group of patients is multiplanar CT. 
Renal arteriography is useful in the preoperative study because it may highlighted a distinct 
vascularisation of the thrombus (observed in 35% to 40% of the cases) allowing to perform a 
preoperative embolization of the kidney, causing the shrinkage of the thrombus and its 
more easily intra-operative removal. 
The prognostic significance of venous involvement and tumour thrombus level remains 
highly controversial. According to the literature in the absence of metastasis, when adjusting 
for clinical and pathologic features, radical nephrectomy with total tumour thrombus 
excision in patients with RCC and level I to III vena caval involvement is associated with a 
cancer specific 5 –year survival rate between 47% and 68% (Staheler & Brkovic, 2000; Belis et 
al., 2000). 
Some authors generally accepted that neoplastic extension in the IVC was not a prognostic 
determining factor (Libertino et al., 1987; Skinner et al., 1989; Ciancio et al., 2010). Some 
others, more recently, have shown that tumour thrombus level is an independent predictor 
of survival (Martı´nez-Salamanca et al., 2011). 
RCC with vascular invasion into the IVC, direct invasion of the vein’s wall appears to be 
an important prognostic factor and should be noted during tumour staging. With no peri-
nephric fat or lymph nodal involvement, patients who undergo tumour excision with 
radical nephrectomy and IVC thrombectomy have an overall and cancer specific 5–year 
survival of 30% to 72% with an operative mortality of 2.7% to 13.5 %. When the thrombus 
locally invades the wall of the vena cava, aggressive resection of the vascular wall with 
reconstruction along with the attainment of negative surgical margins provides a survival 
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benefit (Hatcher et al., 1991). Grafting or reconstitution sometimes is required only in 
those patients with not complete occlusion of IVC and collateral blood flow. In 1913, Berg 
first described nephrectomy and vena caval thrombectomy as primary surgical treatment 
of these patients (Berg, 1913). Usually, in level I and II disease the tumour thrombus can 
safely be excised by means of proximal and distal control of the IVC. In level III and IV 
disease the exposure and isolation of IVC requires liver mobilization with or without the 
use of CBP. Several techniques have been used during the years to remove large caval 
thrombi when distal caval control cannot be achieved below the liver such as cross-
clamping of the supraceliac aorta (Cummings et al., 1979), occlusion of the intra 
pericardial vena cava with simultaneous occlusion of the “porta hepatis” and superior 
mesenteric artery (Skinner et al., 1989), use of an intraoperative venous (cava-atrial) shunt 
(Foster et al.,1988), and cardiopulmonary by pass alone  (Novick & Cosgrove, 1980). The 
use of CBP alone is limited to the period during which the liver and the kidneys undergo 
warm ischemia. Skinner and co-workers reported an average warm ischemia of 14 
minutes ranging from 8 to 20 minutes. Post operative complications occurred in 41% to 
60% of the patients and included transient hyperbilirubinemia, renal dysfunction and 
respiratory failure (Skinner et al., 1989). When the thrombus extends above the diaphragm 
the use of CPB with deep HCCA have been used. Marshall et al., 1984 and Krane et al., 
1984 first demonstrated the feasibility of this approach. The most common post operative 
complications related to this procedure are haemorrhage, coagulopathy, increased 
transient and/or permanent neurologic risk. Novick et al., 1990 in their experience 
reported  up to 60 minutes of safe ischemia with direct visual inspection of the entire vena 
caval lumen in a bloodless field reducing risk of sudden massive intra-operative 
haemorrhage or distal pulmonary tumour Thrombo-embolization. Operative mortality 
rate reported was 4.7% (Novick et al., 1990). Heart surgery have been used more 
frequently to treat intra-cardiac extension of infra-diaphragmatic tumours and the safety 
of this procedure has increased. Chiappini and co-workers in their series of 13 patients 
reported no in-hospital deaths while 2 patients experienced postoperative complications 
such as respiratory failure and bleeding (Chiappini et al., 2002). On the other side, Ruel 
and co-workers in 2001 reported their experience in cavo-atrial thrombus excision in 6 
patients affected by RCC without circulatory arrest (Ruel et al., 2001). During the last 10 
years the traditional approach using CBP and HCCA was revisited. Deep hypothermic 
circulatory arrest was therefore not considered imperative and some studies reported that 
its avoidance may decrease morbidity and mortality. Shinghal et al., in 2003 reported in a 
single patient a novel technique by placing an aortic occlusive balloon in the abdominal 
aorta at the level of the diaphragm, limiting flow in the IVC and maintaining both cerebral 
and spinal cord perfusion during cardiopulmonary bypass (Shingai et al., 2003). In 2005 
Ciancio & Soloway described  a technique that can be safely used to approach RCC with a 
tumour thrombus extending into the supra-diaphragmatic IVC and right atrium through 
a trans-abdominal approach without sternotomy and/or  cardiopulmonary bypass 
utilizing a complete liver mobilization and minimizing the vena caval cross–clamp time. 
The trans-abdominal incision exposes the intra-pericardial IVC and right atrium trans-
diaphragmatically. (Ciancio & Soloway, 2005; Ciancio G, Shirodkar S et al.,2009). Step by 
step description of this technique based on orthotopic liver transplantation was reported 
in 2011 by the same author regarding a cohort of 56 patients with retro-hepatic extension 
of the thrombus and 12 patients  with a supra-hepatic/intra atrial localizations. Mean 
operative time was 5h and 32 min. Five patients required CPB (7.3%). Three patients died 
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in the immediate post operative period (4.4%) (Ciancio G, Gonzalez J,et al., 2011). In 2007 
Chowdhury et al., reported their experience in a cohort of 6 patients with RCC and intra 
atrial tumour thrombus using mild hypothermic CPB and intermittent cross- clamping of 
the supra-celiac abdominal aorta (Chowdhury et al., 2007)  
RCC with vascular invasion into the IVC remains a crucial challenge to the urologic 
oncologist. Complete excision of the tumour together with the thrombus and negative 
margins offers the best chance for patients survival. Surgical resection of these complex 
tumours requires multidisciplinary approach.  
2.1 Adrenal 
The use of CPB to remove the tumour thrombus from adrenocortical carcinoma (ACC) was 
first reported in 1976 (Scully et al., 1976) while the first procedure using HCCA was in 1989 
(Shahian et al., 1989) but because of the poor prognosis of this tumour at this stage and the 
technical difficulties that has to be faced such as the invasion of surrounding organs and 
vascular control/reconstruction, radical surgical resection remains controversial. A recent 
review from France (Chiche et al., 2006) collected the outcome of 32 patients reported in 
literature with cavo-atrial invasion in whom a CPB was used in 26 including 6 under HCCA. 
Reported peri-operative mortality was 3/26 (11.5%) and took place in patients operated 
using CPB alone. 
In their own series of ACC with tumour thrombi extending into the vena cava or in the right 
atrium, they reported the outcome of 15 patients treated by a combination of venous control 
ranging from cross clamping to hepatic vascular exclusion or normo/ipothermic cardio-
pulmonary by-pass. The extension grade C (above the liver) was in 7 patients, including 4 
with atrial thrombi and represents the 7% of the overall series. Of these patients 3 had 
HCCA and 1 (33.3%) died p.o. from multi-organ failure but the patient was cirrhotic with a 
portal thrombosis. 
They concluded that CPB should always be used for tumours extending to the cavo-atrial 
junction or into the right atrium and additional HCCA provides a bloodless field that allow 
a precise dissection of the thrombus while reducing the blood loss.  
2.2 Liver 
Macroscopic vascular invasion (either portal or supra-hepatic) is a major complication of 
hepatocellular carcinoma (HCC). Major vascular invasion is the evolution of microscopic 
vascular invasion over the time so the liver tumour is of the large type at diagnosis and 
usually require major liver resection. 
The natural history of HCC complicated with macroscopic vascular invasion of the portal 
vein, shows a median survival time of only 9 to 10 weeks (Okada et al., 1992).  
Treatments with systemic chemotherapy, intra-arterial chemotherapy or radiofrequency 
ablation result in a dismal survival at 1 year ranging from 7% to 18% (Raul et al., 1994; 
Akashi et al., 1991; Poon et al., 2003). Hepatic resection remains the only option for these 
patients and a recent multicentric study showed that, resected patients lived longer, 
compared to those not treated surgically, with a five-year survival rate of 10% (Pawlik et al., 
2005; Lin et al., 2007).  
Liver tumour with extension to the hepatic veins represents instead a controversial issue 
and its extension in the right atrium (RA) via the inferior vena cava is more uncommon, 
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with percentage of incidence reported of 2.9% by imaging techniques, 0.7% at operation, and 
18.2% at autopsy in Japan (Yogita et al., 2000).  
Therapeutics options at this stage are few and debatable because of the high risk for lung 
metastasis (Masaki et al., 1995) but, on the other hand, the risk of developing a “ball valve 
syndrome”(Hahne & Climie, 1962) or a pulmonary embolism is very high (Fujisaki et 
al.,1991). The overall survival time of these patients with cavo-atrial thrombi and who do 
not undergo operative treatment is reported to be very low: from 3 days to 2 months (Lin et 
al., 2007) 
Liver resection and cavo-atrial thrombectomy remains, in this situation, the only effective 
therapeutic option with reported survival time ranging from 5 to 56 months (Miyazawa et 
al., 2005). 
The firsts authors describing the removal of a tumoural thrombus in the RA from HCC on 
cirrhosis using CBP were Goto et al. in 1986 who removed only the thrombus. Fujisaki et al. 
in 1991 first removed the thrombus along with the primary tumour using CPB hepatic 
vascular exclusion while Hamazaki et al. in 1995 added the use of HCCA in a similar 
situation. Indeed, HCCA was first applied in liver surgery, in a young child to remove atrial 
thrombi from hepatoblastoma, which usually occurs on a normal liver parenchyma, in 1981 
(Ein et al., 1981). 
The majority of patients with HCC has a diseased liver because of the presence of hepatitis 
viruses infection and /or previous alcohol abuse. The presence of hepatic vein, vena cava 
and atrial thrombosis contraindicate liver transplantation and, liver resection with 
thrombectomy, is the only real therapeutic option in this setting (Wu et al., 2000). As 
previously stated, acute pulmonary embolism or congestive heart failure may complicate 
liver tumours involving hepatic vein with tumours thrombi in the inferior vena cava/right 
atrium. This latter situation represent an impending life-threatening condition that should 
be surgically treated as soon as possible (Novick et al., 1990). 
Atrial thrombus removal may be achieved under normothermic CPB and total liver vascular 
exclusion. Tolerance of the cirrhotic liver to normothermic ischemia is reported as safe up to 
33 minutes (Huguet et al., 1994) which is quite similar to the safety time reported to avoid 
neurological complications when using HCCA (McCullough et al., 1999).  
Extracorporeal circulation with HCCA has been increasingly used to remove atrial 
thrombi due to retroperitoneal malignancies (Ogata et al., 2006) but its use in cirrhotic 
patients has been limited, for many years, because of the fear of post-operative liver 
failure and poor outcome. However, in more recent time, we have assisted to an increase 
number of reports where HCCA has been used to remove cavo-atrial thrombi due to HCC 
with no mortality and low morbidity, probably, lower than expected thus, we can assume 
that, a short lasting HCCA, has to be considered safe in a well compensated liver cirrhosis 
(Novick et al., 1990; Yogitaet al., 2000; Ohwada et al., 2008; Florman et al., 2009; Leo et al., 
2010). 
Since the vast majority of patients with HCC and atrial tumour thrombi has large type of 
HCC, a major liver resection is usually required and the possibility of postoperative liver 
failure raises accordingly, liver function tests and indocyanin green retention test, should be 
carried out in these patients in order to demonstrate the presence of a good functional 
reserve (Kawasaki et al., 1995). Furthermore we think that adding a sequential arterial and 
portal embolization of a hemi-liver could lessen the possibilities of post-operative liver 
failure when a major resection is planned (Ogata et al., 2006).  
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Fig. 1. A: Ct scan of a cavo-atrial tumour thrombus (yellow arrow). B and C: Extraction of 
the thrombus, after a left hemi-hepatectomy, from the sectioned left and middle hepatic vein 
ostium (white arrow) using a rings clamps to pull and an index finger, inserted from the 
atriotomy site, to push the thrombus downward. D: Cleaned ostium (red arrow), closed 
atriotomy (black arrow) and distal middle hepatic vein stump (green arrow) to be 
reconstructed. Please note the completely bloodless field of the procedure under 
hypothermic cardiocirculatory arrest.  
2.3 Uterus 
The uterus is seldom the site of origin of a cavo-atrial thrombi owing to two distinct 
tumours: the endometrial stromal sarcoma (ESS) and the “benign” intravenous 
leiomyomatosis (IVL). This latter situation differs from the other types of neoplastic thrombi 
because the endovascular material is represented mainly by myofibroblastic cells, growing 
into the vessel, rather than by a neoplastic thrombotic apposition. 
2.3.1 Endometrial stromal sarcoma 
ESS represents only the 0.2% of all uterine malignancies and it has been described to invade 
the great vessels rarely. In a recent review only 9 patients had a tumour thrombus reaching 
the right atrium, ventricle or the pulmonary artery that underwent radical resection by 
means of total abdominal hysterectomy and thrombectomy. Normothermic CPB was 
reported in 7 out the 9 patients with only 1 (14.3%) complication due to renal acute tubular 
necrosis. No perioperative deaths were reported (Renzulli et al., 2008). 
2.3.2 Intravenous leyomiomatosis 
IVL is an uncommon “benign” tumour of middle age parous women arising from either the 
uterine venous wall or uterine leiomyoma (Nam et al., 2002). It is known also as benign 
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metastatic fibro-leiomyoma because pulmonary nodules (proliferating leiomycites) are often 
present. Although this tumour is usually confined to the pelvis, it sometime extends to the 
right cardiac cavities through the iliac vein and the vena cava (Wakiama et al., 2000) by 
means of intra-vascular proliferation and growth of fibro-myocites which results in an 
extension of the fibro-leiomyoma rather than in a thrombus formation conferring a typical 
consistency and resistance to traction to the endo-vascular proliferation (Galajda et al., 2010).  
IVL with cardiac extension is an exceedingly rare disease first reported in 1907 in an autopsy 
series (Durk, 1907). Since then a further 34 cases have been reported involving the right 
heart (Wakiyama et al., 2000). Patients often have a history of hysterectomy or leiomyoma 
resection and various lengths of intravascular proliferation up to 29 cm with a diagnosis 
performed up to 18 yrs after the primary surgery ( Galajda et al., 2010). 
Complete surgical removal of the uterus and IVL is the therapy of choice (Topcouglu et al., 
2004) and it has been carried out for the first time in 1974 using CPB and HCCA 
(Mandelbaum et al., 1974). 
We came across a similar case (Fig. 2) in whom we performed a total abdominal hysterectomy 
and IVL removal through a cavotomy and atriotomy under CPB and HCCA (Fig. 3). Due to 
the typical consistency of IVL and the usual absence of adhesions the complete heart and retro-
hepatic vena cava cleaning was achieved by simple traction from the infra-renal cavotomy site 
(Fig. 3A) while the iliac portion was stacked and required separate iliac vein incision.  
 
 
Fig. 2. Preoperative ct scan of intra-vascular leiomyomatosis arising from uterine leiomyoma 
(white arrow) extending to the right iliac vein (blue arrow), infra and retro-hepatic vena 
cava (green arrow), right atrium (red arrow) and to the rignt ventricle (yellow arrow). 
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Fig. 3. Same Patient of figure 2. Operative view of the removal, through a cavotomy (A) and 
atriotomy (B), of intravascular leiomyomatosis. Operative specimen removed is shown in C: 
1 and 2 are the right atrial extensions, 3 the right ventricular extension, 4 the caval iliac 
extensions and 5 right ovarian vein involvement. 
2.4 Vena cava 
Leiomysarcomas of the inferior vena cava (IVC) are rare malignant tumours originating 
from the smooth muscle cells of the media layer that typically show three growth patterns: 
extra-luminal, intra-luminal and both (Mingoli et al., 1996). They may be classified 
anatomically according to Chiappini et al., 2002, as for renal tumours, into four types: Type I 
infra-hepatic, type II retro-hepatic, type III supra-hepatic IVC and type IV the thrombus 
extends in the right atrium.  
Patient with type IV was treated and reported by Hassan et al., 2010, using normothermic 
CPB and Pringle’s manoeuvre to remove the atrial thrombus reporting mild 
hyperbilirubinemia and normal renal function. They discussed the possible advantages of 
the technique used, compared to HCCA which they thought to be associated with an 
extended CPB time, increased postoperative bleeding and coagulopathy, and increased 
neurological risk. On the other hand HCCA provides a bloodless surgical field with reduced 
risk of spreading/embolization, and fatal haemorrhage. Furthermore the advantages 
include reduced liver and kidney warm ischemia, reduced risk of incomplete excision, 
optimal visualization of the IVC/right atrial lumen minimizing the need for a too extensive 
retro-peritoneal dissection (Chiappini et al., 2002).  
2.5 Others 
Scattered case reports of ovarian haemangioma (Tamburino et al., 1992), testicular tumour 
(Kanda et al., 1991), embrional carcinoma of the testis (Paule et al., 1991), testicular teratoma 
(Moon et al., 1992) and even pancreatic cancer (Ozben et al., 2007) have been reported so far. 
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The problems when dealing with these situations are almost the same of those reported 
above and at the moment it is impossible to draw any conclusion due the scarcity of the 
cases.  
3. Anesthetic management  
In the following sections, an overview of the main technical features for the management of 
anaesthesia, extracorporeal circulation and hypothermic circulatory arrest for cavo-atrial 
thrombectomy are summarized.  
3.1 Monitoring and anesthesia 
Any operative procedure involving large vessels entail the risk of developing hemodynamic 
instability, mainly due to massive bleeding. Moreover, a number of specific conditions have 
to be taken into consideration, including coexisting multisystemic diseases, non-
physiological conditions associated with CPB and deep HCCA. In light of these concerns, 
patients undergoing cavo-atrial thrombectomy require extensive monitoring to provide 
early warning of conditions that may lead to potentially life-threatening states.  
3.1.1 Monitoring 
An intraoperative electrocardiogram, using the five-leads technique, is the standard 
monitoring procedure always recommended during surgery and anesthesia. In this setting, 
it is useful for the diagnosis of both myocardial ischemia (DII – V5 identify 90% of ischemic 
episodes) and dysrhythmias. 
Intravascular pressure measurements represent the standard technique during this type of 
surgery. Arterial pressure is usually measured by placing a catheter in a peripheral 
(radial, ulnar, brachial) or central (femoral) artery. Direct arterial pressure measurement 
allows monitoring during the pre-CPB stage and nonpulsatile ECC. Moreover, during the 
post-CPB/HCCA period, patients are usually hemodynamically unstable, and close 
surveillance of arterial blood pressure, other than with blood-gas analysis, is of primary 
importance. 
A central venous line (internal jugular, subclavian) for pressure monitoring (central venous 
pressure [CVP]) is influenced by circulating blood volume, venous tone and capacitance, 
and right ventricular function; therefore, a number of pieces of information can be obtained 
from the CVP. A central venous catheter (3 lumens, 7-8.5 Fr) can be used for both pressure 
measurement and inotropic-vasoactive drug administration. Central venous lines can also 
be used for pulmonary artery catheter (PAC) positioning if the patient’s comorbidities 
suggest the monitoring of pulmonary artery pressures, the measurement of cardiac output 
and mixed venous oxygen saturation. Central venous cannulation should be performed 
under ultrasound guidance because up to 30% of patients have some abnormalities of the 
jugular vein anatomy (Carid et al., 1988; Bevilacqua et al., 2005). 
Hemodynamic monitoring is completed with transesophageal echocardiography, which has 
gained widespread use in cardiac operating rooms (where this intervention for cavo-atrial 
invasion is usually performed) because it provides a great deal of information about the 
heart’s global performance during systole and diastole, the valve function and cardiac 
volume loads, as well as morphologic details on thrombotic cardiac invasion from the 
inferior vena cava.  
www.intechopen.com
 Front Lines of Thoracic Surgery 
 
156 
Temperature monitoring. Assessment of accurate central temperature is of primary 
importance in this setting. The core temperature (vital organ temperature) can be measured 
by means of a PAC thermistor, nasopharyngeal probe (provides accurate measurement of 
brain temperature during CPB and HCCA), bladder probe (it may be inaccurate when renal 
blood flow and urine output are decreased), CPB arterial line (temperature of the heat 
exchanger), CPB venous line (reflects core temperature well during CPB, when no active 
cooling or warming is ongoing), or rectal probe (when the tip of the probe rests in stool, the 
measurement may be imprecise) (FIG. 4 & 5).  
 
 
Fig. 4. Monitoring. (NIRS, near infrared spectroscopy; CVC, central venous catheter). 
 
 
Fig. 5. Near infrared spectroscopy. (DHCA Deep Hypothermic Circulatory Arrest; CPB, 
cardiopulmonary bypass). 
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Renal function. Acute kidney injury (AKI) is one of the well-known complications occurring 
during CPB that has significant implications for both short- and long-term outcomes. The 
incidence of acute renal failure rages from 20 to 30% of patients (Kumar & Suneja, 2004). 
Pre-operative renal function is one of the most important factors related to post-CPB AKI. 
The major risk factors for AKI after CPB include advanced age, preexisting kidney disease, 
diabetes mellitus, chronic obstructive pulmonary disease, CPB duration, emergency surgery, 
female sex, left ventricle ejection fraction <40%, and hemodilution on CPB. Hemolysis 
always occurs during CPB, and serum hemoglobin levels rise; therefore, urine output 
should be maintained to avoid tubular damage. Diuretic therapies (mannitol is used 
routinely in CPB priming) are also useful for eliminating the hemodilution induced with the 
onset of CPB. As a consequence, urinary catheter positioning and urine output are the best 
monitoring systems for renal function evaluation. 
3.1.2 Anesthesia  
These patients usually require a smooth induction because wide modifications in vascular 
tone, myocardial contractility, and reductions in venous returns due to increased intra-
thoracic pressures under mechanical ventilation may worsen the organ and tissue perfusion. 
Midazolam or etomidate, in association with an opioid (remifentanil, fentanyl), are useful 
drugs for anesthesia induction; propofol and/or sevoflurane or desflurane can be used for 
anesthesia maintenance, and a nondepolarizing muscle relaxant should be administered for 
the duration of the intervention (Table 1). 
 
 Drug Induction dose 
Hypnotics Propofol 1-1.5 mg/Kg 
 Thiopental 3-4 mg/Kg 
 Etomidate 0.2-0.3 mg/Kg 
 Midazolam 0.1-0.2 mg/Kg 
Opioids Fentanyl 3-10 mcg/Kg 
 Sufentanyl 0.5-1 mcg/Kg 
 Remifentanil 0.1-0.75 mcg/Kg/min  
Muscle relaxants Cisatracurium 0.07- 0.1 mg/Kg 
 Vecuronium 0.07- 0.1 mg/Kg 
 Rocuronium 0.6 mg/Kg 
Table 1. Hypnotics, opioids, and muscle relaxants (induction doses) 
The choice of drug for anesthesia induction and maintenance depends on the patient’s 
general conditions and, in particular, his/her heart, renal, and liver function. In addition, 
antibiotic prophylaxis should be administered at least 30 minutes before skin incision.   
3.2 Cardiopulmonary bypass, deep hypothermic circulatory arrest and neuroprotection 
3.2.1 Cardiopulmonary bypass 
Cardiopulmonary bypass permits blood to bypass the heart and lungs (Fig. 6). 
Venous blood is drained by gravity into an oxygenator (artificial lung), and a pump injects 
it, after oxygenation and removal of CO2, into a great artery (aorta, subclavian, femoral 
artery). Adequate anticoagulation is necessary during the CPB period, and an activated 
clotting time longer than 420-480 seconds is usually considered safe (the optimal target of 
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Fig. 6. Cardiopulmonary bypass. 
ACT is still debated). Anticoagulation is obtained with heparin 300-400 U/kg, and 
supplemental doses of 5000 U can be administered if necessary. Use of heparin-coated 
circuits does not eliminate the need for heparin. The pump flow has to be set at values that 
guarantee an adequate oxygen delivery. “Normal” pump flow is considered to be 2.4 
l/min/m2, although recent studies have demonstrated that a redistribution of flow toward 
organs occurs during CPB in both normothermia and hypothermia (Slater et al., 2001). 
Muscle flow is significantly reduced during CPB, and if flow is reduced, splacnic, renal and 
cerebral flow decrease as well, in that order. During CPB, blood pressure depends on pump 
flow, total arterial impedance and haematocrit. During CPB, blood pressure is less 
important in determining global perfusion if pump flow is adequate, but minimal values of 
blood pressure may be significant in providing specific regional flows; therefore, during 
mild to moderate hypothermia (30-34°C), the blood pressure is generally maintained at 
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approximately 70 mm Hg. During CPB and HCCA, the loss of flow auto regulation (<20°C 
and for several hours after HCCA) is still debated, but pressure levels as low as 30-40 mm 
Hg are considered safe values (Croughwell et al., 1992). Despite several techniques for 
cerebral protection have been developed, central nervous system dysfunction associated 
with cardiac surgery is very frequent, with an incidence that depends on the type of 
intervention (up to 65%) (Arrowsmith et al., 2000). Apart from ischemic events, cognitive 
dysfunction has been observed within the first postoperative week in more than 80% of 
patients undergoing coronary artery bypass grafting under CPB, and at five years after 
surgery, some degree of neuropsychological dysfunction can be observed in up to 35% of 
patients (Arrowsmith et al., 2000). A number of risk factors have been identified, and they 
can be divided into patient-related and technology-related factors. The patient-related 
factors are age>70 year old, cerebrovascular disease, aortic atherosclerosis, and diabetes 
mellitus; the technology-related factors are open chamber procedures, CPB duration >90 
minutes, use of bubble rather than membrane oxygenators, and circulatory arrest. Apart 
from open chamber procedures, all the other risk factors have to be taken into consideration 
when cavo-atrial thrombectomy with CPB and HCCA is performed.  
3.2.2 Deep hypothermic circulatory arrest 
After CPB has been started, the temporary interruption of cerebral blood flow is a necessary 
condition to remove the thrombus from the vena cava and, in such cases, from the right 
atrium. Interruption of cerebral blood flow has been associated with a high incidence of 
neurologic injury because the brain is susceptible to ischemic injury within minutes of the 
onset of circulatory arrest as a result of its high metabolic rate and limited reserves 
(Harrington et al., 2003). The physiologic basis for hypothermia as a neuroprotective 
strategy is its ability to reduce the cerebral oxygen metabolic rate and the accumulation of 
toxic metabolites. In adults, a decrease in core temperature leads to a reduction in the 
cerebral metabolic rate that increases in ischemic tolerance from 2-3 minutes 
(normothermia) to 20-34 minutes (17°C) (Reich et al., 1999). However, the optimal level of 
hypothermia is still debated. Studies based on electroencephalographic monitoring have 
shown that a median nasopharyngeal temperature of 18°C allows electrocortical silence 
(Stecker et al., 2001). Today, based on the results of several studies, HCCA at 18°C is 
considered safe for durations of up to 40 minutes (Griepp, 2001). It has been also suggested 
that hypothermia provides neurological protection through mechanisms other than the 
cerebral metabolic rate. In the face of an incomplete understanding of the involved 
mechanisms, hypothermia remains the most efficacious intervention for preventing 
ischemic brain injuries. In addition to systemic hypothermia, topical cooling, obtained by 
packing the head with ice, can be used to prevent passive warming of the brain during 
circulatory arrest, but consensus on this adjunctive strategy is still lacking because re-
warming during circulatory arrest could be negligible (Reich et al., 1999). After the targeted 
core temperature has been reached, the pump is turned off, allowing brain protection 
during surgery performed in a bloodless field. HCCA has several potential adverse 
consequences. Achieving the target temperature prolongs the duration of the CPB period, 
thus amplifying problems related to CPB (loss of pulsatile flow, injury to blood elements, 
risk of embolization, coagulation system derangements, etc.). Re-warming increases the 
cerebral metabolic rate and has the potential to make the brain vulnerable to ischemic injury. 
With the aim of limiting brain injuries, a short period (10 minutes) of hypothermic 
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reperfusion is achieved before re-warming, and maintaining a temperature gradient of less 
than 10°C in the heat exchanger and avoiding complete re-warming are usually performed.  
Currently, there is no class of drug representing the standard of practice, but some drugs 
can be used as adjunctive strategies for cerebral protection. A number of drugs cause EEG 
burst suppression, resulting in a reduction in the cerebral metabolic rate by approximately 
50%, but the most used of these drugs is thiopental at a dose of 5-8 mg/kg. The 
administration of thiopental results in EEG burst suppression for few minutes at 
normothermia. Thiopental and/or steroids are administered before circulatory arrest in 
some centres, without a clear demonstration of beneficial effects.  
3.2.3 pH management during hypothermia 
There is an inverse relationship between gas solubility and blood temperature. When blood 
temperature decreases, an apparent respiratory alkalosis occurs due to a decrease in PaCO2 
and an increase in pH. To compensate for this PaCO2 reduction, CO2 can be added to the 
oxygenator (pH-stat management) or the CPB gas sweep rate can be reduced. The technique 
of pH-stat management was commonly used until the mid-1980s, but there is more recent 
evidence that pH-stat management can increase the incidence of postoperative cognitive 
dysfunction when CPB lasts longer than 90 minutes (Murkin et al., 1995). It has been 
suspected that the increase in CO2 should increase the cerebral blood flow during perfusion 
phases, uncoupling flow and metabolism. The most used α-stat (not temperature-correcting) 
requires that neutrality be maintained at only 37°C, and it permits hypothermic alkaline 
drift. Thus, additional CO2 is not needed. Cellular trans-membrane pH gradients, protein 
functioning, and enzyme activity are more normal when the pH is allowed to drift into the 
alkaline range, in parallel with the temperature-dependent pKa of protein and the neutral 
pH of water. Moreover, a relatively alkaline pH is beneficial before the ischemic insult of 
circulatory arrest. Despite considerable laboratory and animal research into these 
mechanisms, substantial controversy remains over which strategy produces the best clinical 
outcomes (Duebener et al., 2002).   
3.2.4 Coagulation management  
Coagulation system management during and after CPB is based on the administration of 
heparin, followed by neutralization with protamine, and this approach has been unchanged 
for almost 50 years. Heparin binds to antithrombin-III (AT-III), potentiating the action of 
AT-III (more than 1000-fold) to inhibit thrombin and factor Xa most importantly (but also 
factors IXa, XIa, and XIIa). After central venous administration, heparin’s effect peaks within 
1 minute. The onset of CPB increases the circulating blood volume by approximately 1500 
ml, reducing the heparin blood concentration; therefore, 5000 U of heparin are added to the 
CPB prime. Before CPB, heparin is administered at a dose of 300-400 U/kg to obtain ACT 
for 420-480 seconds, and successive supplemental doses are guided by monitoring the ACT. 
Some centres monitor blood heparin concentrations. ACT is prolonged by hypothermia and 
hemodilution. After CPB weaning is successfully achieved and a satisfactory spontaneous 
circulation is restored, heparin anticoagulation must be reversed with protamine 
administration. The most used protamine-heparin ratio is 0.6-1 mg/100 U. Protamine must 
always be administered slowly to prevent adverse hemodynamic effects. After protamine 
administration, ACT should return to a value no more than 10% above the basic value. If 
more prolonged, heparin residual activity is likely, and additional doses of protamine 
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should be administered. During CPB, antifibrinolytic agents (ξ-aminocaproic acid or 
tranexamic acid) have beneficial effects in restoring coagulation equilibrium. 
Antifibrinolytics act as lysine analogues that bind to the lysine-binding sites of plasmin and 
plasminogen. ξ -aminocaproic acid can be administered at a dose of 100-150 mg/kg in bolus 
form, followed by 10-15 mg/kg/h or a 50 mg/kg bolus followed by 20-25 mg/kg/h. 
Tranexamic acid can be administered at a dose of 10-20 mg/kg followed by 1-2 mg/kg/h, 
although some centres prefer a 5 g bolus and repeat bolus to a total of 15 g. Post-bypass 
bleeding is common after CPB/HCCA. Evaluation of haemostasis and correct intervention 
are key factors for preventing indiscriminate use of transfusion medicine. After surgical 
haemostasis has been achieved, the first approach is the confirmation of adequate heparin 
neutralization (heparinase ACT, protamine titration test, thromboelastography-TEG). In 
addition, a test of platelet function should be available (TEG maximal amplitude, Platelet-
Function-Analyzer-100). Finally, the fibrinolysis pathway must be explored (TEG lysis 
index). Packed red blood cells must be available at every moment of the intervention, and 
fresh frozen plasma and platelets should be prepared in case of established coagulation 
abnormalities (very frequent in this population of patients) to replace coagulation factors 
and platelets.  
4. Conclusions 
In conclusion we think that CPB with HCCA should be considered for atrial thrombi 
removal in patient affected by several abdominal malignancies such as renal, adrenal 
carcinomas, primary liver tumours also in presence of a well compensated liver cirrhosis, 
uterine endometrial stromal tumours and intravascular leiomyomatosis, vena cava 
leiomysarcoma and others, because it is simpler and safer compared to CPB alone. It permits 
the careful cleaning of the vena cava, right atrium, ventricle and even of the pulmonary 
artery in a bloodless field which entails in a lower recurrence rate. Mortality and morbidity 
seem to be the same when compared to CPB alone but further studies are necessary due to 
the small number of patients. 
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